Schneider-Littfeld in Advisory Board

Johannes Schneider Littfeld, former top manager at Ottobock, takes over chairmanship of Mecuris Advisory Board

Munich, 04.07.2019 - The Munich based medical technology startup Mecuris GmbH won industry expert Johannes Schneider Littfeld as Chairman of the Advisory Board. The company Mecuris offers a digital workshop for the creation and individualisation of prostheses and orthoses. After a successful startup stage, Johannes Schneider Littfeld will set the course for the future development in the growth stage of Mecuris.

With over 30 years of experience in medical technology and executive positions with leading companies in the orthopaedic technology sector, Johannes Schneider Littfeld, MSc, has now been appointed Chairman of the Advisory Board.

Johannes Schneider Littfeld, MSc, studied Biomedical Engineering in Giessen. After several years in medical research he started his career as a Consultant at Sudler&Hennessey. Furthermore, he held positions as Managing Director/ CEO with Ferring Biotechnik, Becton Dickinson, Bauerfeind and many years as Corporate Vice President M&A and CEO Neurostimulation at Otto Bock HealthCare. He serves on multiple international advisory boards in the life sciences industry.

Due to his extensive expertise and industry knowledge, he was appointed Chairman of the Advisory Board of Mecuris on June 27, 2019. In this function he will strengthen the startup in the establishment phase and lead it into the growth stage. "I look forward to the task and the trust that is placed in me. The decisive factor for me was the committed team, whose interdisciplinary composition drives innovative ideas and processes forward. At the same time, I am aware of the challenge to lead the long-established craft of orthopedic technology into the digital age with our innovative approach, which can certainly be regarded as disruptive," says Littfeld. Manuel Opitz, CEO at Mecuris, "We are convinced that Johannes Schneider Littfeld, with his many years of expertise and international industry knowledge, will be a valuable partner to lead Mecuris to success." Dr. Christian Schneider, Managing Partner of lead investor Vesalius Biocapital, agrees: "We, management and investors, fully trust in the experience of our new chairman. Together with the strong Mecuris management team, he will take the company to the next level of commercialisation."

In the coming months, Mecuris will introduce the first software solutions for orthopaedic technology and open up to markets outside of Europe with its existing product range of prosthetic fitting parts and orthotic braces.

About Mecuris GmbH

Mecuris teams up with certified prosthetists and orthotists (CPOs) to move orthopaedic care into the digital age. Bringing together 3D technologies into one intuitive Mecuris Solution Platform the company found a way to simplify the CPOs work and transform the way to design and use orthopaedic devices. Mecuris enriches wearers' lives by enabling medical professionals to design their product ideas on our intuitive digital platform - without any CAD design knowledge. This means patients can quickly regain their mobility, show their individuality and become active again faster. Thanks to full CE-mark and ISO certification, Mecuris' products meet the highest safety standards and are reimbursed by all health insurance funds in Germany.

Mecuris - You. Create.

Press contact Mecuris GmbH:

Eva Stahl, Head of Marketing
Lindwurmstr. 11,
80337 Munich, Germany
Phone: +49 89 552623-86
Email: pr@mecuris.com
Web: www.mecuris.com

Download this press release as PDF file [151 kB]

Share this